News
ABX-CRO at TRP 2022
This year we will be hosting partner at the 4th annual Targeted Radiopharmaceuticals Summit Europe. Meet ABX-CRO at the TRP 2022 Dec 6-8 | Amsterdam, Netherlands.
ABX-CRO at SNMMI 2022
Meet ABX-CRO executives at the SNMMI 2022 Annual Meeting June 11-14 | Vancouver, BC, at booth no. # 649. Celebrate with us our inauguration of our Boston-based US branch ABX-CRO Inc., further strengthening our global operations,...
Andreas Fintelmann joins ABX-CRO as Managing Director
Andreas Fintelmann, leading radiopharmaceutical and precursor industry expert and executive joins ABX-CRO as managing director to support the further global expansion and growth of ABX-CRO. Andreas Fintelmann states “I am delighted to join ABX-CRO and reunite with...
Webinar: Establishing an Expert Network for Your Radiopharmaceutical Drug Development Program
Preclinical and clinical evaluation of radiopharmaceuticals can be sometimes seen as straightforward compared to non-radioactive molecules as the injected doses are often below toxic doses. However, the development of theranostics requires highly specific expertise...
ABX-CRO has selected Flex Databases CTMS and eTMF to further increase quality of clinical trial management
Speaking about why ABX-CRO decided to choose Flex Databases, Dr. Ulrike Schorr-Neufing said: The possibility of on-premise solutions for CTMS and eTMF as well as the flexibility of the different modules for managing clinical trials suits ABX-CRO very well. Flex...
New Alliance: DRIVE™-MRT
ABX-CRO (Dresden, Germany), the globally leading full-service CRO for molecular imaging and radiotherapy, ONCODESIGN (ALONC -FR0011766229), a French biopharmaceutical company dedicated to precision medicine, Covalab (Bron, France), a biotechnology company specializing in the development and production of custom antibodies and CheMatech (Dijon, France), the European leader in the design announce their partnership. This strategic collaboration will launch the DRIVE™-MRT (Molecular RadioTherapy) solution. This innovative, premium service offer for therapeutic development is unique in nuclear medicine; it encompasses the full drug discovery process of theranostics, from therapeutic target validation, radiolabeled biological vector generation, lead optimization, preclinical candidate drug generation and IND, to the design and management of clinical trials.